ABI-008

Celgene · Phase 1 active Small molecule

At a glance

Generic name	ABI-008
Also known as	nab-docetaxel
Sponsor	Celgene
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer (PHASE1, PHASE2)
ABI-008 Trial in Patients With Metastatic Breast Cancer (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ABI-008 CI brief — competitive landscape report
ABI-008 updates RSS · CI watch RSS
Celgene portfolio CI